Delivering on the Promise of Long-Acting Technologies
TAGline • 2021By Susan Swindells* and Mark Harrington This issue of TAGline explores the exciting opportunities and challenges that come with the development of long-acting formulations for the prevention and treatment of infectious diseases. For many years to date, patients and providers have welcomed long-acting medications for other conditions such as schizophrenia, osteoporosis, and contraception. These delivery…
HIV Vaccines, Passive Immunization, and Antibody Gene Transfer
Pipeline PDF • 2020The Future of Biomedical HIV Prevention Trials: Researcher Viewpoints and Community Survey
Publication • 2020This report aims to make more accessible to community advocates discussions around ethical conduct of biomedical prevention trials in the era of PrEP. In early 2019, TAG, along with Black AIDS Institute and the HIV Vaccine Trials Network developed an online survey, asking for diverse community input on existing and developing biomedical prevention areas of…
Ensuring Universal Access to COVID-19 Diagnosis, Treatment and Prevention
Publication • 2020TAG and the Center for Economic and Social Rights produced this joint publication, as part of CESR’s COVID-19 “Recovering Rights” series of briefs.
The HIV Vaccines, Passive Immunization, and Antibody Gene Transfer Pipeline
Pipeline • 2018July 2018 by Richard Jefferys The most important news in preventive HIV vaccine research over the past year is the opening of a Phase IIb trial testing the efficacy of a prime-boost approach developed by Janssen Vaccines & Prevention B.V., part of the Janssen Pharmaceutical Companies of Johnson & Johnson. The trial, known as Imbokodo…
The Role of Vaccines and Cures in HIV Elimination
TAGline • 2018By Richard Jefferys The development of highly effective approaches to HIV treatment and prevention—in the form of combination antiretroviral therapy (ART) and pre-exposure prophylaxis (PrEP)—stands among the most impressive scientific achievements in human history. As detailed elsewhere in this issue of TAGline, the widespread implementation of these interventions has the potential, at least theoretically, to…
Pharma Lies, People Die: Myth-Busting Fact Sheet on Medicine Development and Pricing
TAGline • 2018By Bryn Gay, HCV Project Director, TAG and Claudine Guerra, CUNY DOWNLOAD to print this article as a poster (A1 size) The current leaders of the United States manufacture crises, media optics, and catchy sound bites to side step actual responsibility for tackling immensely complex policy issues like extortionately high prescription drug prices. The American…
Keeping an Eye on Intellectual Property Issues in HIV Cure and Prevention Research
TAGline • 2018By Richard Jefferys, Basic Science, Vaccines, and Cure Project Director, TAG The history of antiretroviral (ARV) drug development offers many examples of compounds that were originally discovered and investigated by publicly funded academic researchers, before being acquired and ushered to market by pharmaceutical companies. Among them is azidothymidine (AZT), the first approved ARV, which was…
Whose Intellect? Whose Property? A Blueprint for Bringing Down the Pharma IP House of Cards
TAGline • 2018By JD Davids, TAGline Guest Editor and Suraj Madoori, U.S. and Global Health Policy Director, TAG As the Trump administration makes noise about the high price of pharmaceuticals while doubling down on its commitment to “protect the engine of American ingenuity,” this issue of TAGline dives deep into the rhetoric and realities of intellectual property …
2018 TAG Update
Publication • 2018I want to thank all of you for the support that enabled the successes TAG achieved this past year. Despite a challenging political climate and continued attacks against those living with or at risk of contracting HIV, tuberculosis (TB), or hepatitis C virus (HCV), we’ve made significant progress. As you’ll see In TAG Update, in…